Budget impact analysis of introducing infliximab subcutaneous for the treatment of Inflammatory Bowel Disease in Latvia

被引：0
|
作者：
Yoo, H. K. [1 ]
Jang, M. Y. [1 ]
Kwon, T. S. [2 ]
机构：
[1] Celltr Healthcare, Global Market Access, Incheon, South Korea
[2] Celltr Healthcare, Global Market, Incheon, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P893
引用
收藏
页码：1008 / 1009
页数：2
相关论文
共 50 条
  • [41] COMPARISON OF SUBCUTANEOUS AND INTRAVENOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOWED NO DIFFERENCES IN IMMUNOGENICITY OR TREATMENT PERSISTENCE AT ONE YEAR
    Morda, F.
    Hancox, S.
    Black, C. J.
    Selinger, C.
    [J]. DIGESTIVE AND LIVER DISEASE, 2024, 56 : S239 - S239
  • [42] Comparison of subcutaneous and intravenous infliximab in patients with inflammatory bowel disease showed no differences in immunogenicity or treatment persistence at 1 year
    Hancox, Sarah
    Morda, Francesco
    Black, Christopher J.
    Selinger, Christian Philipp
    [J]. FRONTLINE GASTROENTEROLOGY, 2024,
  • [43] THE CLINICAL AND FINANCIAL IMPACT OF MEASURING INFLIXIMAB LEVELS AND ANTIBODIES TO INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS
    O'Reilly, S.
    Keegan, D.
    Byrne, K.
    Sheridan, J.
    Mulcahy, H. E.
    Doherty, G. A.
    Cullen, G.
    [J]. GUT, 2017, 66 : A2 - A3
  • [44] BUDGET IMPACT OF SUBCUTANEOUS INFLIXIMAB IN COMPARISON TO INTRAVENOUS INFLIXIMAB IN THE MANAGEMENT OF AUTOIMMUNE DISEASES IN GREECE
    Mortaki, K.
    Rigopoulos, P.
    Stratopoulos, A.
    Avgerinou, M.
    Kougioumtzoglou, I
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S68 - S68
  • [45] Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease
    Buhl, Sine
    Steenholdt, Casper
    Rasmussen, Maria
    Borghede, Marta K.
    Brynskov, Jorn
    Thomsen, Ole O.
    Ainsworth, Mark A.
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 (07) : 1210 - 1217
  • [46] Treatment of inflammatory bowel disease with Infliximab. Experience in 25 patients
    Simian, Daniela
    Isabel Quijada, Maria
    Lubascher, Jaime
    Acuna, Raul
    Quera, Rodrigo
    [J]. REVISTA MEDICA DE CHILE, 2013, 141 (09) : 1158 - 1165
  • [47] Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab
    Orfanoudaki, E.
    Gazouli, M.
    Foteinogiannopoulou, K.
    Theodoraki, E.
    Legaki, E.
    Koutroubakis, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S375 - S376
  • [48] Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease
    Schnitzler, Fabian
    Fickler, Herma H.
    Ferrante, Marc
    Noman, Maja
    Van assche, Gert A.
    Spitz, Bernard
    Vermeire, Severine
    Rutgeerts, Paul J.
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A144 - A144
  • [49] Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease
    Siegel, CoreyA.
    Levy, L. Campbell
    Mackenzie, Todd A.
    Sands, Bruce E.
    [J]. INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : 1 - 6
  • [50] Ppd testing in patients starting infliximab for treatment of inflammatory bowel disease
    Minor, Melissa
    Ghimire, Sanjay
    Singh, Surya
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S408 - S408
12345